Comparison of the mutagenicity of aristolochic acid I and aristolochic acid II in the gpt delta transgenic mouse kidney

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 743, Issue 1-2, 2012, Pages 52-58

  Xing, Guozhen ^a,b   Qi, Xinming ^a   Chen, Min ^a,b   Wu, Yuanfeng ^a,b   Yao, Jun ^a,b   Gong, Likun ^a   Nohmi, Takehiko ^c   Luan, Yang ^a   Ren, Jin ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

Aristolochic acid; DNA adducts; Mutagenesis

Indexed keywords

ARISTOLOCHIC ACID; ARISTOLOCHIC ACID I; ARISTOLOCHIC ACID II; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CARCINOGENICITY; COMPARATIVE STUDY; CONTROLLED STUDY; DNA ADDUCT; IN VIVO STUDY; KIDNEY; MALE; MOUSE; MUTAGENICITY; MUTATION RATE; NONHUMAN; PLASMA; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; ARISTOLOCHIC ACIDS; CARCINOGENS; DNA ADDUCTS; DNA DAMAGE; ESCHERICHIA COLI PROTEINS; KIDNEY; MICE; MICE, TRANSGENIC; MUTAGENS; PENTOSYLTRANSFERASES;

MUS; MUS MUSCULUS;

EID: 84862815654     PISSN: 13835718     EISSN: 18793592     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2011.12.021     Document Type: Article

References (40)

1. Vanherweghem J.L., Depierreux M., Tielemans C., Abramowicz D., Dratwa M., Jadoul M., Richard C., Vandervelde D., Verbeelen D., Vanhaelen-Fastre R. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993, 341:387-391.
2. Nortier J.L., Martinez M.C., Schmeiser H.H., Arlt V.M., Bieler C.A., Petein M., Depierreux M.F., De Pauw L., Abramowicz D., Vereerstraeten P.J.L., Vanherweghem L. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N. Engl. J. Med. 2000, 342:1686-1692.
3. Grollman A.P., Shibutani S., Moriya M., Miller F., Wu L., Moll U., Suzuki N., Fernandes A., Rosenquist T., Medverec Z., Jakovina K., Brdar B., Slade N., Turesky R.J., Goodenough A.K., Rieger R., Vukelic M., Jelakovic B. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:12129-12134.
4. Grosse Y., Baan R., Straif K., Secretan B., El Ghissassi F., Bouvard V., Benbrahim-Tallaa L., Guha N., Galichet L., Cogliano V. A review of human carcinogens - part A: pharmaceuticals. Lancet Oncol. 2009, 10:13-14.
5. Stiborova M., Frei E., Arlt V.M., Schmeiser H.H. Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy. Mutat. Res. 2008, 658:55-67.
6. NTP Report on Carcinogens 2011, U.S. Department of Health and Human Services, Public Health Service, National Toxicology Program, Research Triangle Park, NC, 499 pp. twelfth edition.
7. Li W., Gong S., Wen D., Che B., Liao Y., Liu H., Feng X., Hu S. Rapid determination of aristolochic acid I and II in Aristolochia plants from different regions by beta-cyclodextrin-modified capillary zone electrophoresis. J. Chromatogr. A 2004, 1049:211-217.
8. Li L., Gao H.M., Wang Z.M., Wang W.H. Determination of aristolochic acid A in Guanxinsuhe preparations by RP-HPLC. Zhongguo Zhong Yao Za Zhi 2006, 31:122-124.
9. Schmeiser H.H., Pool B.L., Wiessler M. Identification and mutagenicity of metabolites of aristolochic acid formed by rat liver. Carcinogenesis 1986, 7:59-63.
10. Krumbiegel G., Hallensleben J., Mennicke W.H., Rittmann N., Roth H.J. Studies on the metabolism of aristolochic acids I and II. Xenobiotica 1987, 17:981-991.
11. Xiao Y., Ge M., Xue X., Wang C., Wang H., Wu X., Li L., Liu L., Qi X., Zhang Y., Li Y., Luo H., Xie T., Gu J., Ren J. Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity. Kidney Int. 2008, 73:1231-1239.
12. Xiao Y., Xue X., Wu Y.F., Xin G.Z., Qian Y., Xie T.P., Gong L.K., Ren J. beta-Naphthoflavone protects mice from aristolochic acid-I-induced acute kidney injury in a CYP1A dependent mechanism. Acta Pharmacol. Sin. 2009, 30:1559-1565.
13. Shibutani S., Bonala R.R., Rosenquist T., Rieger R., Suzuki N., Johnson F., Miller F., Grollman A.P. Detoxification of aristolochic acid I by O-demethylation: less nephrotoxicity and genotoxicity of aristolochic acid Ia in rodents. Int. J. Cancer 2010, 127:1021-1027.
14. Pfau W., Schmeiser H.H., Wiessler M. Aristolochic acid binds covalently to the exocyclic amino group of purine nucleotides in DNA. Carcinogenesis 1990, 11:313-319.
15. Arlt V.M., Stiborova M., Schmeiser H.H. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 2002, 17:265-277.
16. Schmeiser H.H., Bieler C.A., Wiessler M., van Ypersele de Strihou C., Cosyns J.P. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res. 1996, 56:2025-2028.
17. Schmeiser H.H., Schoepe K.B., Wiessler M. DNA adduct formation of aristolochic acid I and II in vitro and in vivo. Carcinogenesis 1988, 9:297-303.
18. Pfau W., Schmeiser H.H., Wiessler M. 32P-postlabelling analysis of the DNA adducts formed by aristolochic acid I and II. Carcinogenesis 1990, 11:1627-1633.
19. Dong H., Suzuki N., Torres M.C., Bonala R.R., Johnson F., Grollman A.P., Shibutani S. Quantitative determination of aristolochic acid-derived DNA adducts in rats using 32P-postlabeling/polyacrylamide gel electrophoresis analysis. Drug Metab. Dispos. 2006, 34:1122-1127.
20. Shibutani S., Dong H., Suzuki N., Ueda S., Miller F., Grollman A.P. Selective toxicity of aristolochic acids I and II. Drug Metab. Dispos. 2007, 35:1217-1222.
21. Singh R., Farmer P.B. Liquid chromatography-electrospray ionization-mass spectrometry: the future of DNA adduct detection. Carcinogenesis 2006, 27:178-196.
22. Chan W., Yue H., Poon W.T., Chan Y.W., Schmitz O.J., Kwong D.W., Wong R.N., Cai Z. Quantification of aristolochic acid-derived DNA adducts in rat kidney and liver by using liquid chromatography-electrospray ionization mass spectrometry. Mutat. Res. 2008, 646:17-24.
23. Chen L., Mei N., Yao L., Chen T. Mutations induced by carcinogenic doses of aristolochic acid in kidney of Big Blue transgenic rats. Toxicol. Lett. 2006, 165:250-256.
24. Kohara A., Suzuki T., Honma M., Ohwada T., Hayashi M. Mutagenicity of aristolochic acid in the lambda/lacZ transgenic mouse (MutaMouse). Mutat. Res. 2002, 515:63-72.
25. Schmeiser H.H., Pool B.L., Wiessler M. Mutagenicity of the two main components of commercially available carcinogenic aristolochic acid in Salmonella typhimurium. Cancer Lett. 1984, 23:97-101.
26. Gotzl E., Schimmer O. Mutagenicity of aristolochic acids (I, II) and aristolic acid I in new YG strains in Salmonella typhimurium highly sensitive to certain mutagenic nitroarenes. Mutagenesis 1993, 8:17-22.
27. Maier P., Schawalder H., Weibel B. Low oxygen tension, as found in tissues in vivo, alters the mutagenic activity of aristolochic acid I and II in primary fibroblast-like rat cells in vitro. Environ. Mol. Mutagen. 1987, 10:275-284.
28. Nohmi T., Katoh M., Suzuki H., Matsui M., Yamada M., Watanabe M., Suzuki M., Horiya N., Ueda O., Shibuya T., Ikeda H., Sofuni T. A new transgenic mouse mutagenesis test system using Spi- and 6-thioguanine selections. Environ. Mol. Mutagen. 1996, 28:465-470.
29. Schmeiser H.H., Frei E., Wiessler M., Stiborova M. Comparison of DNA adduct formation by aristolochic acids in various in vitro activation systems by 32P-post-labelling: evidence for reductive activation by peroxidases. Carcinogenesis 1997, 18:1055-1062.
30. Masumura K., Matsui M., Katoh M., Horiya N., Ueda O., Tanabe H., Yamada M., Suzuki H., Sofuni T., Nohmi T. Spectra of gpt mutations in ethylnitrosourea-treated and untreated transgenic mice. Environ. Mol. Mutagen. 1999, 34:1-8.
31. Cariello N.F. Software for the analysis of mutations at the human hprt gene. Mutat. Res. 1994, 312:173-185.
32. Adams W.T., Skopek T.R. Statistical test for the comparison of samples from mutational spectra. J. Mol. Biol. 1987, 194:391-396.
33. Mei N., Arlt V.M., Phillips D.H., Heflich R.H., Chen T. DNA adduct formation and mutation induction by aristolochic acid in rat kidney and liver. Mutat. Res. 2006, 602:83-91.
34. Chan W., Zheng Y., Cai Z. Liquid chromatography-tandem mass spectrometry analysis of the DNA adducts of aristolochic acids. J. Am. Soc. Mass Spectrom. 2007, 18:642-650.
35. Shibutani S., Bonala R.R., Rosenquist T., Rieger R., Suzuki N., Johnson F., Miller F., Grollman A.P. Detoxification of aristolochic acid I by O-demethylation; less nephrotoxicity and genotoxicity of aristolochic acid Ia in rodents. Int. J. Cancer 2009.
36. Broschard T.H., Wiessler M., von der Lieth C.W., Schmeiser H.H. Translesional synthesis on DNA templates containing site-specifically placed deoxyadenosine and deoxyguanosine adducts formed by the plant carcinogen aristolochic acid. Carcinogenesis 1994, 15:2331-2340.
37. Arlt V.M., Wiessler M., Schmeiser H.H. Using polymerase arrest to detect DNA binding specificity of aristolochic acid in the mouse H-ras gene. Carcinogenesis 2000, 21:235-242.
38. Moriya M., Slade N., Brdar B., Medverec Z., Tomic K., Jelakovic B., Wu L., Truong S., Fernandes A., Grollman A.P. TP53 mutational signature for aristolochic acid: an environmental carcinogen. Int. J. Cancer 2011, 129:1532-1536.
39. Arlt V.M., Stiborova M., Henderson C.J., Thiemann M., Frei E., Aimova D., Singh R., Gamboa da Costa G., Schmitz O.J., Farmer P.B., Wolf C.R., Phillips D.H. Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice. Carcinogenesis 2008, 29:656-665.
40. Singh R., Gaskell M., Le Pla R.C., Kaur B., Azim-Araghi A., Roach J., Koukouves G., Souliotis V.L., Kyrtopoulos S.A., Farmer P.B. Detection and quantitation of benzo[a]pyrene-derived DNA adducts in mouse liver by liquid chromatography-tandem mass spectrometry: comparison with 32P-postlabeling. Chem. Res. Toxicol. 2006, 19:868-878.